SG11202006379UA - Human antibodies to influenza hemagglutinin - Google Patents
Human antibodies to influenza hemagglutininInfo
- Publication number
- SG11202006379UA SG11202006379UA SG11202006379UA SG11202006379UA SG11202006379UA SG 11202006379U A SG11202006379U A SG 11202006379UA SG 11202006379U A SG11202006379U A SG 11202006379UA SG 11202006379U A SG11202006379U A SG 11202006379UA SG 11202006379U A SG11202006379U A SG 11202006379UA
- Authority
- SG
- Singapore
- Prior art keywords
- human antibodies
- influenza hemagglutinin
- hemagglutinin
- influenza
- antibodies
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 title 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title 1
- 101710176177 Protein A56 Proteins 0.000 title 1
- 239000000185 hemagglutinin Substances 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622480P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015029 WO2019147867A1 (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006379UA true SG11202006379UA (en) | 2020-07-29 |
Family
ID=66286952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006379UA SG11202006379UA (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11780907B2 (en) |
| EP (1) | EP3743442A1 (en) |
| JP (2) | JP7372925B2 (en) |
| KR (1) | KR20200115517A (en) |
| CN (1) | CN111670195A (en) |
| AU (1) | AU2019212480A1 (en) |
| BR (1) | BR112020014849A2 (en) |
| CA (1) | CA3088194A1 (en) |
| CL (1) | CL2020001884A1 (en) |
| CO (1) | CO2020009043A2 (en) |
| EA (1) | EA202091563A1 (en) |
| IL (1) | IL275884A (en) |
| MA (1) | MA51681A (en) |
| MX (1) | MX2020007772A (en) |
| PH (1) | PH12020551051A1 (en) |
| SG (1) | SG11202006379UA (en) |
| WO (1) | WO2019147867A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230107644A1 (en) * | 2020-04-01 | 2023-04-06 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
| JP2023551666A (en) * | 2020-11-23 | 2023-12-12 | ヴィア・バイオテクノロジー・インコーポレイテッド | Antibodies against influenza A virus |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| CA2608656A1 (en) * | 2005-05-16 | 2006-11-23 | Morphotek, Inc. | Regulated vectors for selection of cells exhibiting desired phenotypes |
| PT2374818E (en) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| MX2009002174A (en) | 2006-09-07 | 2009-03-12 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof. |
| EP1947423A1 (en) | 2007-01-16 | 2008-07-23 | Sony Deutschland Gmbh | Distance, orientation and velocity sensitive controller |
| WO2008140415A1 (en) | 2007-05-11 | 2008-11-20 | Temasek Life Sciences Laboratory Limited | H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance |
| CN101883789B (en) | 2007-09-13 | 2014-10-08 | 淡马锡生命科学研究院有限公司 | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof |
| JP5490695B2 (en) | 2007-09-13 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | Monoclonal antibodies specific for hemagglutinin from influenza virus H5 subtype and uses thereof |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| WO2009099394A1 (en) | 2008-02-05 | 2009-08-13 | Temasek Life Sciences Laboratory Limited | Binding protein and epitope-blocking elisa for the universal detection of h5-subtype influenza viruses |
| CN102046656A (en) | 2008-03-28 | 2011-05-04 | 航道生物技术有限责任公司 | Neutralizing molecules to viral antigens |
| CN102216327A (en) | 2008-07-25 | 2011-10-12 | 生物医学研究所 | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP3301116A1 (en) | 2008-08-25 | 2018-04-04 | Dana Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
| EP2379591A4 (en) | 2008-12-24 | 2012-10-17 | Temasek Life Sciences Lab Ltd | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof |
| EP2380976A4 (en) | 2008-12-25 | 2012-11-07 | Univ Osaka | Human anti-human influenza virus antibody |
| ES2934102T3 (en) | 2009-05-11 | 2023-02-16 | Janssen Vaccines & Prevention Bv | Human binding molecules that can neutralize the H3N2 influenza virus and uses thereof |
| JP2012526839A (en) | 2009-05-13 | 2012-11-01 | シー レーン バイオテクノロジーズ， エルエルシー | Neutralizing molecule against influenza virus |
| PT2975051T (en) | 2009-06-26 | 2021-05-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| ME02646B (en) | 2010-02-08 | 2017-06-20 | Regeneron Pharma | Common light chain mouse |
| CA2849668A1 (en) | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| RU2635999C2 (en) | 2010-06-17 | 2017-11-17 | ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи | Antibodies suitable for passive immunization against influenza |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| US20130289246A1 (en) | 2010-09-30 | 2013-10-31 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| CA2838999C (en) | 2011-07-14 | 2021-02-16 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |
| ITRM20110606A1 (en) | 2011-11-16 | 2013-05-17 | Ist Superiore Sanita | LATTOFERRINA PEPTIDES FOR USE AS HIGH-SPECIMEN INHIBITORS OF VIRUS INFLUENCE INFECTION. |
| SG11201402780UA (en) | 2011-12-02 | 2014-10-30 | Aimm Therapeutics Bv | Influenza a virus specific antibodies |
| AU2012347878B2 (en) | 2011-12-05 | 2018-05-10 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| MY170407A (en) | 2012-03-08 | 2019-07-27 | Crucell Holland Bv | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| CN104968367B (en) | 2012-11-13 | 2018-04-13 | 弗·哈夫曼-拉罗切有限公司 | Antihemagglutinin antibody and application method |
| TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
| KR20140118682A (en) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | Composition comprising two or more influenza A viruses neutralizing binding molecules |
| PL3052192T3 (en) | 2013-10-02 | 2021-04-06 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
| RU2720282C1 (en) | 2014-02-04 | 2020-04-28 | Контрафект Корпорейшн | Antibodies suitable for passive immunization against influenza, and compositions thereof, combinations and methods of using |
| CN106132987A (en) | 2014-03-27 | 2016-11-16 | 豪夫迈·罗氏有限公司 | Anti-influenza B hemagglutinin antibody and using method |
| CN104031118B (en) | 2014-06-19 | 2016-04-13 | 天津大学 | The novel affinity peptide aglucon of murine polyomavirus capsomere and design screening method thereof |
| TWI702229B (en) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | Human antibodies to influenza hemagglutinin |
| US10435462B2 (en) | 2015-03-31 | 2019-10-08 | Viro Dynamics Corporation | Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza |
| US11135282B2 (en) * | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| CN107667114B (en) | 2015-06-01 | 2021-07-02 | 免疫医疗有限责任公司 | Neutralizing anti-influenza binding molecules and uses thereof |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2020221450A1 (en) | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies and methods for treatment of influenza a infection |
-
2019
- 2019-01-24 CA CA3088194A patent/CA3088194A1/en active Pending
- 2019-01-24 MX MX2020007772A patent/MX2020007772A/en unknown
- 2019-01-24 AU AU2019212480A patent/AU2019212480A1/en active Pending
- 2019-01-24 CN CN201980009873.XA patent/CN111670195A/en active Pending
- 2019-01-24 JP JP2020539709A patent/JP7372925B2/en active Active
- 2019-01-24 MA MA051681A patent/MA51681A/en unknown
- 2019-01-24 WO PCT/US2019/015029 patent/WO2019147867A1/en unknown
- 2019-01-24 US US16/964,579 patent/US11780907B2/en active Active
- 2019-01-24 KR KR1020207022064A patent/KR20200115517A/en active Search and Examination
- 2019-01-24 BR BR112020014849-0A patent/BR112020014849A2/en unknown
- 2019-01-24 EA EA202091563A patent/EA202091563A1/en unknown
- 2019-01-24 EP EP19719656.1A patent/EP3743442A1/en active Pending
- 2019-01-24 SG SG11202006379UA patent/SG11202006379UA/en unknown
-
2020
- 2020-07-06 IL IL275884A patent/IL275884A/en unknown
- 2020-07-07 PH PH12020551051A patent/PH12020551051A1/en unknown
- 2020-07-17 CL CL2020001884A patent/CL2020001884A1/en unknown
- 2020-07-23 CO CONC2020/0009043A patent/CO2020009043A2/en unknown
-
2023
- 2023-02-28 JP JP2023030129A patent/JP2023060018A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7372925B2 (en) | 2023-11-01 |
| WO2019147867A9 (en) | 2019-11-07 |
| PH12020551051A1 (en) | 2021-08-23 |
| US20210371505A1 (en) | 2021-12-02 |
| KR20200115517A (en) | 2020-10-07 |
| JP2023060018A (en) | 2023-04-27 |
| AU2019212480A1 (en) | 2020-09-10 |
| BR112020014849A2 (en) | 2020-12-08 |
| MA51681A (en) | 2021-05-05 |
| JP2021511043A (en) | 2021-05-06 |
| WO2019147867A1 (en) | 2019-08-01 |
| CO2020009043A2 (en) | 2020-07-31 |
| CA3088194A1 (en) | 2019-08-01 |
| IL275884A (en) | 2020-08-31 |
| EP3743442A1 (en) | 2020-12-02 |
| CL2020001884A1 (en) | 2020-12-11 |
| US11780907B2 (en) | 2023-10-10 |
| MX2020007772A (en) | 2020-09-18 |
| EA202091563A1 (en) | 2020-10-08 |
| CN111670195A (en) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252659A0 (en) | Human antibodies to influenza hemagglutinin | |
| IL277858A (en) | Antibodies specific to human nectin4 | |
| ZA201803783B (en) | Human immunodeficiency virus neutralizing antibodies | |
| MA43108A (en) | ANTIBODY NEUTRALIZING THE HUMAN RESPIRATORY SYNCYTIAL VIRUS | |
| IL248392A0 (en) | Human antibodies to middle east respiratory syndrome -coronavirus spike protein | |
| CL2016001879A1 (en) | Human antibodies to pd-l1 | |
| IL247870A0 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| HK1256033A1 (en) | Use of peptides to stimulate the immune system | |
| BR112017001684A2 (en) | pulse protein product preparation ("yp810") | |
| EP3551228A4 (en) | Antibodies to human alpha-synuclein | |
| IL280332A (en) | Composition containing influenza vaccine | |
| EP3528827A4 (en) | Influenza hemagglutinin protein vaccines | |
| HK1255839A1 (en) | Antibody which specifically binds to human crth2 | |
| GB201609742D0 (en) | Improvements relating to antibodies | |
| IL275884A (en) | Human antibodies to influenza hemagglutinin | |
| HK1254342A1 (en) | Influenza potency assays | |
| DK3247394T3 (en) | PHARMACEUTICAL FORMULATION INCLUDING ANTI-EGFR ANTIBODY | |
| HK1249864A1 (en) | Modified h7 hemaggluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence | |
| EP3423090C0 (en) | Novel influenza antigens | |
| GB201719561D0 (en) | Vaccine to enhance ADCC | |
| IT201600131819A1 (en) | PREPARATION FOR ORAL SPRAY | |
| PT3390441T (en) | Human immunodeficiency virus neutralizing antibodies | |
| ITUA20164040A1 (en) | PROCEDURE FOR THE PREPARATION OF POLIMORFO A | |
| CL2015002917S1 (en) | Dental mallet | |
| TH1601000713A (en) | New antibodies against human TSLP receptors |